	US 12,239,702 B2
	Vaccination with replicon particles and oil adjuvant
Mark A. Mogler, Ames, IA (US); Erin Strait, Spring Hill, KS (US); and Ruud Philip Antoon Maria Segers, Boxmeer (NL)
Assigned to INTERVET INC., Rahway, NJ (US)
Appl. No. 16/769,329
Filed by Intervet Inc., Madison, NJ (US)
PCT Filed Dec. 3, 2018, PCT No. PCT/EP2018/083297 § 371(c)(1), (2) Date Jun. 3, 2020, PCT Pub. No. WO2019/110481, PCT Pub. Date Jun. 13, 2019.
Claims priority of provisional application 62/607,101, filed on Dec. 18, 2017.
Claims priority of provisional application 62/594,342, filed on Dec. 4, 2017.
Prior Publication US 2020/0323975 A1, Oct. 15, 2020
Int. Cl. A61K 39/193 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 39/00 (2006.01); A61K 47/26 (2006.01)

CPC A61K 39/193 (2013.01) [A61K 9/1075 (2013.01); A61K 47/26 (2013.01); A61K 9/0021 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55566 (2013.01)]

19 Claims

1. A vaccine comprising an alphavirus RNA replicon particle encoding an antigen originating from an animal pathogen, wherein the vaccine also comprises an oil adjuvant which comprises a mineral oil and a non-mineral oil, wherein the mineral oil is a liquid paraffin oil and wherein the non-mineral oil is Vitamin E acetate.